Some opposite data were published some years ago about a possible predictive role of TP53 mutation on paclitaxel sensitivity in breast cancer [22,23]; Johnson et al [23] proposed a model in which the loss of p53 function reduced the G1 block thus enhancing the efficacy of paclitaxel during mitosis. The gene discussed is TP53; the disease is breast carcinoma.